| Outcome Measures: |
Primary: Detection of T2DM susceptibility gene expression in newly diagnosed T2DM patients, To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of newly diagnosed T2DM patients and compared with those in healthy subjects., 1 month after fresh sample collection|Detection of T2DM susceptibility gene expression in controls, To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of controls and compared with those in newly diagnosed T2DM patients., 1 month after fresh sample collection|Correlation between T2DM susceptibility gene expression and clinicopathological features, Incidence of clinical pancreatic diseases under expression differences in T2DM susceptibility genes, 6 months after obtaining the clinicopathological results | Secondary: Baseline BMI of newly diagnosed with T2DM patients with different genotypes, Baseline BMI of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline waist hip ratio (WHR) of newly diagnosed with T2DM patients with different genotypes, Baseline WHR of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline fasting plasma glucose (FPG) of newly diagnosed with T2DM patients with different genotypes, Baseline FPG of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline HbA1c of newly diagnosed with T2DM patients with different genotypes, Baseline HbA1c of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline TC of newly diagnosed with T2DM patients with different genotypes, Baseline TC of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline TG of newly diagnosed with T2DM patients with different genotypes, Baseline TG of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline HDL-C of newly diagnosed with T2DM patients with different genotypes, Baseline HDL-C of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline LDL-C of newly diagnosed with T2DM patients with different genotypes, Baseline LDL-C of newly diagnosed with T2DM patients, 1 month of completion for individual screening|Baseline BMI of controls with different genotypes, Baseline BMI of controls, 1 month of completion for individual screening|Baseline WHR of controls with different genotypes, Baseline WHR of controls, 1 month of completion for individual screening|Baseline FPG of controls with different genotypes, Baseline FPG of controls, 1 month of completion for individual screening|Baseline HbA1c of controls with different genotypes, Baseline HbA1c of controls, 1 month of completion for individual screening|Baseline TC of controls with different genotypes, Baseline TC of controls, 1 month of completion for individual screening|Baseline TG of controls with different genotypes, Baseline TG of controls, 1 month of completion for individual screening|Baseline HDL-C of controls with different genotypes, Baseline HDL-C of controls, 1 month of completion for individual screening|Baseline LDL-C of controls with different genotypes, Baseline LDL-C of controls, 1 month of completion for individual screening
|
